Compare IHS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHS | VIR |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 773.5M |
| IPO Year | 2021 | 2019 |
| Metric | IHS | VIR |
|---|---|---|
| Price | $7.36 | $6.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $9.32 | ★ $25.73 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $1,765,825,000.00 | $16,860,000.00 |
| Revenue This Year | $3.49 | N/A |
| Revenue Next Year | $2.77 | $48.05 |
| P/E Ratio | $5.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $4.16 |
| 52 Week High | $8.00 | $14.45 |
| Indicator | IHS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 61.51 |
| Support Level | $7.45 | $6.49 |
| Resistance Level | $7.96 | $6.89 |
| Average True Range (ATR) | 0.27 | 0.47 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 65.79 | 83.17 |
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.